Ozon Pharmaceuticals received 31 registration certificates in 2024. They cover both prescription and over-the-counter segments in various pharmacological groups. Since 2021, the company's portfolio of registration certificates has grown by 20% from 445 to 535. Currently, 246 drugs are at various stages of development and registration, which will ensure high...

Ozon Pharmaceuticals Group completed the installation of industrial equipment on the production line for active pharmaceutical substances in Togliati. Installation of three 2000-liter bioreactors and chromatographs was completed. New lines will allow to produce up to 1 million vials of lyophilizates, 5 million prefilled syringes and more than 4 million vials...

Ozon Pharmaceuticals is considering exporting its products; these plans are now in the early stages, the company's investor relations director Dmitry Kovalenko said. Export potential of the products is an additional upside that may shoot up after 2027, when the company launches biosimilars, he said.

Ozon Pharmaceuticals' sales in 2024 amounted to 321 mln packs of pharmaceuticals, up 13% year-on-year. Major growth in sales in volume terms came from the government procurement segment, where more than 93.7 million packs were sold during the year, up 44% year-on-year in 2023. Retail sales grew by 4% to 227.5 million packs.